Artificial intelligence company Paige has partnered with the Ohio State University Wexner Medical Center and its affiliated community hospitals to conduct a study on the effectiveness of AI tools in diagnosing cancer. The collaboration aims to evaluate how AI can improve the accuracy, efficiency, and costs of cancer diagnosis in a community hospital setting.
In this study, the Ohio State University Wexner Medical Center will use Paige’s FDA-approved AI-powered pathology algorithm, known as Paige Prostate Suite, to analyze changes in prostate cancer diagnoses with the assistance of AI. The primary focus will be on how AI tools can enhance the ability of general surgical pathologists to detect, grade, and quantify prostate cancers.
The study will consider various factors, such as patient treatment and management pathways, subspecialist access, and the level of confidence in both traditional and AI-assisted diagnoses. By examining these variables, the researchers hope to gain insights into the overall utility and economic impact of AI in diagnosing cancer.
Paige Prostate Suite has already shown promising results in improving prostate cancer detection. This research collaboration will provide valuable data on the specific benefits that AI can bring to the field of pathology. Additionally, the study will help healthcare professionals understand how to integrate AI tools effectively into existing diagnostic processes.
The partnership between Paige and the Ohio State University Wexner Medical Center demonstrates the growing interest in leveraging AI technology to advance cancer diagnosis and improve patient outcomes. This study has the potential to contribute valuable knowledge and shape the future of cancer diagnostics using AI algorithms.